93M1 Share Price Performance
Recent 93M1 News & Updates
No updates
MPH Health Care AG Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
Sep 16, 2025
- Earnings per share (EPS)
- 7.48
- Gross Margin
- 100.00%
- Net Profit Margin
- 49.04%
- Debt/Equity Ratio
- 3.7%
MPH Health Care AG Competitors
About 93M1
- Founded
- 2008
- Employees
- 2
- CEO
- WebsiteView website
MPH Health Care AG, an investment company, engages in the healthcare business in Germany. The company operates Beauty, Pharma, and Real Estate segments. It offers medicalaesthetic beauty operations and treatments, as well as the operation and provision of medical infrastructures for partner companies; and pharmaceuticals and medical products in the therapeutic areas of oncology, HIV/AIDS, neurology, rheumatology, other chronic diseases, and aesthetic medicine. The company also focuses on therapies for cancer, HIV, rheumatology, and other chronic diseases. In addition, the company offers plastic and aesthetic treatments; and develops and sells pharmaceutical and medical products; and provides related services, as well as medical devices for the aesthetic surgery and specialist medical centres. In addition, it is involved in the provision of cytostatic solutions; and real estate activities. The company was formerly known as MPH Mittelständische Pharma Holding AG and changed its name to MPH Health Care AG in 2017. The company was founded in 2008 and is based in Berlin, Germany.
German Market Performance
- 7 Days: 1.7%
- 3 Months: 1.9%
- 1 Year: 20.1%
- Year to Date: 6.9%
Over the last 7 days, the market has risen 1.7%, driven by gains of 12% in the Communication Services sector. On the other hand, with a decline of 4.4%, the Consumer Discretionary sector is lagging behind. The market is up 20% over the last 12 months. As for the next few years, earnings are expected to grow by 16% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading